These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36037566)

  • 1. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
    Tomita Y; Larkin J; Venugopal B; Haanen J; Kanayama H; Eto M; Grimm MO; Fujii Y; Umeyama Y; Huang B; Mariani M; di Pietro A; Choueiri TK
    ESMO Open; 2022 Oct; 7(5):100564. PubMed ID: 36037566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
    ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
    Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
    ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
    ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
    Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
    Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
    Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
    Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
    Bilen MA; Rini BI; Voss MH; Larkin J; Haanen JBAG; Albiges L; Pagliaro LC; Voog EG; Lam ET; Kislov N; McGregor BA; Lalani AA; Huang B; di Pietro A; Krulewicz S; Robbins PB; Choueiri TK
    Clin Cancer Res; 2022 Feb; 28(4):738-747. PubMed ID: 34789480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
    N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
    Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
    ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
    Larkin J; Oya M; Martignoni M; Thistlethwaite F; Nathan P; Ornstein MC; Powles T; Beckermann KE; Balar AV; McDermott D; Gupta S; Philips GK; Gordon MS; Uemura H; Tomita Y; Wang J; Michelon E; di Pietro A; Choueiri TK
    Oncologist; 2023 Apr; 28(4):333-340. PubMed ID: 36576173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Grimm MO; Oya M; Choueiri TK; Motzer RJ; Schmidinger M; Quinn DI; Gravis-Mescam G; Verzoni E; Van den Eertwegh AJM; di Pietro A; Mariani M; Wang J; Thomaidou D; Albiges L
    Eur Urol; 2024 Jan; 85(1):8-12. PubMed ID: 37852850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
    Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
    Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
    Leslie I; Boos LA; Larkin J; Pickering L
    Expert Rev Anticancer Ther; 2020 May; 20(5):343-354. PubMed ID: 32293937
    [No Abstract]   [Full Text] [Related]  

  • 16. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
    Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
    Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.